Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
Ticker SymbolMGX
Company nameMetagenomi Inc
IPO dateFeb 09, 2024
CEODr. Brian C. Thomas, Ph.D.
Number of employees202
Security typeOrdinary Share
Fiscal year-endFeb 09
Address5959 Horton St
CityEMERYVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94608
Phone15108714880
Websitehttps://metagenomi.co/
Ticker SymbolMGX
IPO dateFeb 09, 2024
CEODr. Brian C. Thomas, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data